John Floberg, MD, PhD | Find a Doctor ...

Dr. John M. Floberg

Claim this profile

University of Wisconsin Carbone Cancer Center - University Hospital

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
5 reported clinical trials
18 drugs studied

Affiliated Hospitals

Image of trial facility.
University Of Wisconsin Carbone Cancer Center - University Hospital
Image of trial facility.
University Of Wisconsin - Carbone Cancer Center

Clinical Trials John M. Floberg is currently running

Image of trial facility.

Radioactive Drug Therapy

for Prostate Cancer

This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
Recruiting1 award Phase 216 criteria
Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3

More about John M. Floberg

Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments John M. Floberg has experience with
  • Bicalutamide
  • Buserelin
  • Degarelix
  • Flutamide
  • Goserelin
  • Histrelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does John M. Floberg specialize in?
Is John M. Floberg currently recruiting for clinical trials?
Are there any treatments that John M. Floberg has studied deeply?
What is the best way to schedule an appointment with John M. Floberg?
What is the office address of John M. Floberg?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security